Table 4

Efficacy outcomes according to eGFR category in patients treated with alteplase

	eGFR (mL/min/1.73 m²)	Event rate (%)	Crude effect size (95% CI)	P value	Adjusted effect size (95% CI)*	P value
Primary outcome
mRS score 0–1 at 90 days	≥90	293 (61.2)	1		1
	60–89	86 (51.5)	0.67 (0.47 to 0.96)	0.03	0.98 (0.65 to 1.46)	0.90
	<60	26 (52.0)	0.69 (0.38 to 1.23)	0.21	1.13 (0.57 to 2.24)	0.72
Secondary outcome
mRS score 0–2 at 90 days	≥90	363 (75.8)	1		1
	60–89	108 (64.7)	0.59 (0.40 to 0.86)	0.006	0.87 (0.56 to 1.36)	0.55
	<60	31 (62.0)	0.52 (0.28 to 0.96)	0.036	0.82 (0.40 to 1.72)	0.60
European Health-Related Quality of Life at 90 days	≥90	80 (70 to 90)	1		1
	60–89	80 (60 to 90)	−5.84 (−9.71 to −1.97)	0.003	−3.50 (−7.45 to 0.45)	0.08
	<60	80 (70 to 90)	0.72 (−6.24 to 7.67)	0.84	2.87 (−4.22 to 9.96)	0.43
Barthel index score≥95 at 90 days	≥90	331 (71.2)	1		1
	60–89	95 (60.1)	1.00 (0.64 to 1.53)	0.94	1.01 (0.65 to 1.56)	0.96
	<60	28 (71.8)	2.23 (0.94 to 5.28)	0.94	0.45 (0.19 to 1.07)	0.07

Data are expressed as n/N (%), effect size (95% CI), median (IQR) or p value. Scores on the mRS range from 0 to 6, with 0 indicating no disability, 3 indicating moderate disability, and 6 indicating death.
The association between eGFR as a categorical variable and the efficacy and safety outcome was estimated by calculating the ORs with 95% CIs using binary logistic regression models. β-coefficient with its 95% CI was calculated using general linear model for the outcome of European quality of life visual analogue scale.
*The models were adjusted for age, sex, baseline National Institutes of Health Stroke Scale, history of hypertension, history of antiplatelet and anticoagulant drug use, onset-to-needle time and bridging thrombectomy.
eGFR, estimated glomerular filtration rate; mRS, modified Rankin Scale.